OcuNexus' Investors

Domain Associates, L.L.C.

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.

Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

www.domainvc.com

GBS Venture Partners

GBS is now the largest specialist life science investor in Australia and New Zealand with over $400m in funds under management from seed through to expansion stage. GBS believes that life science investment requires specific expertise for consistent high level performance and the GBS founders built the business with this in mind, each element of the business reflecting commitment to this approach.

GBS invests in and adds value to unlisted high growth companies involved in innovative technologies such as:

·        Human therapeutics and diagnostics

·        Animal therapeutics and diagnostics

·        Medical devices

·        Health information technology

·        Agribusiness, food and environmental technology

www.gbsventures.com.au

BioPacific Ventures

BioPacific Ventures is a venture capitalist specializing in the convergence of food and health with a focus on prevention, nutrition, food technology and AgBiotech. BioPacific Ventures pursues attractive life science investment opportunities based in New Zealand and Australia and takes lead or co-investment positions in rounds ranging from NZ$2 to NZ$10 million.

BioPacificVentures is supported by strategic and financial investors with global reach and industry specific expertise. The largest investor is the world’s biggest food company, Nestlé; the largest local investor is the leading agribusiness firm PGG Wrightson.

While investments are made across the whole life science spectrum, BioPacificVentures has a particular focus on opportunities in the emerging "wellness through prevention" market, reflecting the increasing trend in healthcare towards the prevention of chronic diseases. Opportunities of particular interest include functional and medical foods, nutraceuticals, cosmeceuticals, skin care, dietary supplements, infant and sports nutrition, immune stimulation and anti-aging therapies.

www.directcapital.co.nz/BioPacificVentures.aspx

RMI PaRTNERS

RMI Partners is a venture company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe and Russia, RMI Partners is one of the largest investors in life sciences. The company makes global investments in a variety of therapeutic areas.

RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies is based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.

RMI Partners is currently managing the venture fund RusnanoMedInvest (RMI, a subsidiary of JSC RUSNANO), which was created in 2012 to develop innovative projects in the field of medicine and pharmaceutics. RMI’s portfolio includes companies from Russia, USA, UK and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies, many of which successfully completed an initial public offering (IPO) on NASDAQ, or were purchased by strategic buyers.

RMI Partners is a member of Invest Europe, the association which is representing Europe’s private equity, venture capital and infrastructure sectors.

www.rmivc.com